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We describe acute myopathy following I-131 treatment for hyperthyroidism due to Graves Disease (GD) in an adolescent. A
15 year-old diagnosed with GD required treatment with radioactive iodine (I-131) therapy. Six weeks post I-131, he developed
generalized muscle cramps. The CK was 19.800U/L, the total thyroxine was 2.3mcg/dL (29.6nmol/L SI) and the estimated free
thyroxine (EFT) was 0.5ng/dL (6.4 pmol/L SI). The ALT was 112U/L and AST was 364U/L (normal <35U/L). The muscle
cramps and CK elevation normalized ﬁve months after initiation of thyroid replacement therapy. This observation shows that
acute myopathy can rarely occur in pediatric patients with GD following treatment with I-131.
1.Introduction
Graves Disease (GD) is uncommon in children with an
estimated incidence of 1 per 10,000 [1]. GD accounts for
95% of the cases of hyperthyroidism in children and is more
frequent in those with a familial history of autoimmune
thyroid disease [2]. Although pharmacological therapy with
antithyroid drugs (ATDs) is the ﬁrst-line therapy in pediatric
GD, long-term remission rates of GD in children are less
than 25% [3]. Thus, deﬁnitive treatment with radioactive
iodine (RAI, I-131) or surgery is required for the majority of
individualswithGD[3,4].WhenI-131isused,thetreatment
goal is hypothyroidism which typically occurs 2–4 months
after the administered dose [5, 6].
Muscle abnormalities can occur in hypothyroidism via
mechanisms that are unclear [7]. Hypothyroidism-related
myopathy has been observed in adults and children [8], with
a wide spectrum of problems including myalgias, proximal
myopathy, and muscle hypertrophy [7]. Elevation of serum
creatine kinase (CK), associated with rhabdomyolysis and
renal complications, has been reported [9–12]. Fifty seven
to 90% hypothyroid individuals can have CK elevations
[13, 14], a phenomenon not observed in hyperthyroidism
[15].
Acute myopathy with onset during the acute hypothy-
roidism following treatment of GD is rare in adults [16].
Severe rhabdomyolysis, a more severe state where elevation
of muscle enzymes is additionally associated with myo-
globinuria, elevated creatinine, and renal failure, has also
been observed in this setting [17, 18]. In children, myopathy
with hypothyroidism is rare [19], and we are unaware of
reports of acute myopathy following 131-I treatment in
the pediatric population. We now describe acute myopathy
following I-131 treatment for hyperthyroidism due to GD in
an adolescent.
2.CaseReport
A 15-year-old male was diagnosed with GD. At presen-
tation, there was goiter (estimated 40–60 grams of thy-
roid tissue). The total thyroxine (T4) was 27.8mcg/dL
(357.8nmol/L SI) (normal 4.5–12.5mcg/dL), estimated
free thyroxine (EFT) 6.6ng/dL (85pmol/L SI) (normal
1.1–2.2ng/dL), thyrotropin-stimulating hormone (TSH)
<0.01uIU/mL (normal 0.35–4.35 uIU/mL); total triiodothy-
ronine (T3) was 490ng/dL (7.5 nmol/L SI) (normal 47–186
ng/dL) (Table 1).2 International Journal of Pediatric Endocrinology
Table 1: Biochemical test results over time.
T4 (5–10.6mcg/dL) EFT (1.1–2.2ng/dL) CK (24–195U/L) ALT (0–35U/L) AST (0–35U/L)
Diagnosis of GD 27.8 6.6 — 20 27
Myopathy onset 2.3 0.5 19,800 242 112
5 months after 131-I 10.5 2 69 14 16
T4, total thyroxine levels; EFT, estimated free thyroxine; CK, Creatine kinase; ALT, alanine aminotransferase; ALT, aspartate aminotransferase. Normal ranges
are shown in parenthesis.
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Figure 1: Serial changes in creatine kinase (CK) and total thyroxine
(T4) levels. GD: onset of Graves Disease, 131-I: radioactive iodine
treatment.
His past medical history was unremarkable. He was
treated with 20 mg of methimazole (MMI) per day and
atenolol.Onemonthintotreatment,hedevelopedneutrope-
nia. The MMI was discontinued, and the patient was treated
with 15.2mCi of 131-I ﬁve days later. The 123-I uptake prior
to 131-I therapy was >95% in the neck. A 99-Tc scan showed
diﬀuse uptake over the thyroid. At the time of treatment,
the T4 was 19.5mcg/dL (251nmol/L SI), and the EFT was
6.5ng/dL (83.6pmol/L SI). Four weeks later, the goiter had
decreased in size, the WBC was 3.1 · 103 /uL, the absolute
neutrophil count (ANC) was 2.3 · 103 cells/uL, and the T4
was 13.4mcg/dL (172.4 nmol/L SI).
Six weeks after 131-I treatment, he developed sud-
den onset of generalized muscle cramps. The CK was
19.800U/L (normal 24–195U/L), with an increased CK-
MB fraction of 13.9ng/mL (normal <5ng/mL). Troponin-
I levels and an electrocardiogram were normal. The total
T4 was 2.3mcg/dL (29.6nmol/L SI), and the EFT was
0.5ng/dL (6.4pmol/L SI). The ALT was 112U/L, and AST
was 364U/L (normal <35U/L). There was no evidence of
myoglobinuria or electrolyte abnormalities. Renal function
was normal. He received intravenous hydration and was
placed on levothyroxine (125mcg/day). He continued to
have milder muscle cramps which resolved over the next
three months. Neurological evaluation did not reveal an
intrinsic myopathy. Five months after starting levothyroxine
therapy, CK levels normalized (Figure 1).
3. Discussion
Acute myopathy in GD was initially reported in an adult
treated with 131-I, who presented with muscle cramps
and CK elevation six weeks after treatment, a condition
that resolved with the correction of the hypothyroid state
[16]. Severe rhabdomyolysis was reported in a patient with
papillary thyroid cancer two weeks after total thyroidectomy
[17]. Adults have been reported to have developed either
myopathy or rhabdomyolysis following the sudden onset of
hypothyroidism [18, 20, 21] .T h em a g n i t u d eo fC Ke l e v a -
tions in these individuals was postulated to be related to the
degree of hypothyroidism [14]; however, such correlations
have not been found by others [22]. Acute myopathy has
also been described in individuals undergoing GD treatment
with thionamides [15, 18, 23]. CK elevations during medical
treatment of GD, in the absence of a hypothyroid state in two
children, have been reported too [19].
The pathogenesis of hypothyroid myopathy is not yet
w e l lu n d e r s t o o d .I th a sb e e ns u g g e s t e dt h a tt h y r o x i n ed e ﬁ -
ciency leads to an abnormal glycogenolysis [21], metabolic
disturbances in mitochondrial oxidative metabolism and
triglyceride turnover, which impairs muscle function [24].
Muscle biopsies performed in this setting reveal nonspeciﬁc
changes, including type II ﬁber atrophy [25]. It has also been
suggested that a reversible, acquired glycogen storage and
mitochondrial disorder is a part of hypothyroid myopathy
[13, 26].
Although a muscle biopsy was not performed, formal
neurological evaluation did not reveal a potential for under-
lying myopathic condition. Following normalization of CK
levels,theyhaveremainednormaleveninthefaceofrigorous
physical activity. Of note, the decline in T4 levels subsequent
to 131-I therapy in our patient was also not unusual in
comparison with that reported in pediatric patients [5].
Thus, at present, a speciﬁc cause for myopathy, other than
acute onset hypothyroidism, cannot be discerned.
Over the past two decades of 131-I use in the treatment
of GD in pediatric patients at our institution, this is the only
individualtohavedevelopedthisproblem.Thus,weestimate
the incidence of myopathy following 131-I therapy on GD to
be less than 0.5% in children.
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